Indivior Pharmaceuticals (INDV) announced it will report first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation at 8:00 a.m. EDT with CEO Joe Ciaffoni and leadership team. The company highlighted a cost impact model showing its monthly injectable buprenorphine treatment (SUBLOCADE) may reduce staffing burdens and costs in correctional facilities compared to other opioid use disorder medications.

Indivior Pharmaceuticals priced a $450 million offering of 0.625% convertible senior notes due 2031, upsized from the initially announced $400 million. The notes have a conversion price of approximately $41.66 per share (35% premium to market price) and will mature on March 15, 2031. Net proceeds of approximately $437.7 million will be used to repay existing debt ($239 million plus $102 million cash on hand), repurchase approximately 2.4 million shares ($75 million), and fund general corporate purposes.

Indivior Pharmaceuticals announced its intention to offer $400 million in convertible senior notes due 2031 in a private placement to qualified institutional buyers. The company plans to use approximately $239 million of net proceeds to repay existing term loan and revolving credit facility borrowings, up to $75 million for share repurchases, and the remainder for general corporate purposes. The notes will be convertible into common stock under specified conditions and redeemable after March 2029.

Indivior Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on February 26, 2026, followed by a leadership webcast. The company also completed its redomiciliation from the United Kingdom to the United States and provided 2026 financial guidance projecting total net revenue between $1,125-$1,195 million, with SUBLOCADE net revenue expected at $905-$945 million.

Indivior reported strong Q3 results, upgrading full-year guidance for Sublocade sales to $825-$845 million. The company is executing a three-phase growth strategy focused on increasing U.S. sales and achieving expense savings.

A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.

Addex Therapeutics announced that it will present preclinical data on its GABAB positive allosteric modulator cough program at the American Cough Conference. The company's lead drug candidate is ready to start IND enabling studies.

The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.

Indivior cuts its FY24 revenue guidance due to lower-than-expected SUBLOCADE revenue amid competition from a competing injectable product, leading to a decline in the company's stock price.

Indivior PLC investors are advised to contact the Portnoy Law Firm to recover losses from alleged corporate wrongdoing during the class period of February 22, 2024 to July 8, 2024. The complaint claims the company exaggerated its ability to predict the impact of legislation, inflated financial outlooks, and made misleading statements about its business and prospects.

Indivior PLC (INDV) is facing a class action lawsuit alleging securities fraud between February 22, 2024 and July 8, 2024. The lawsuit claims the company made false statements and concealed information about the negative impact of certain legislation on its financial prospects and the performance of its products.

Indivior PLC is facing a securities fraud lawsuit for allegedly making false and misleading statements about its products and financial performance, leading to investor losses.